JOSH WOLFE

Josh Wolfe stands as a prominent figure in the venture capital landscape, widely recognized as the visionary Managing Partner and co-founder of Lux Capital. Since co-founding the firm in 2000, Wolfe has been at the forefront of identifying and nurturing companies that push the boundaries of science and technology. His leadership has positioned Lux Capital as a leading investor in what he often refers to as "frontier tech" or "deep tech," transforming audacious scientific concepts into tangible, market-disrupting realities.

At Lux Capital, Josh Wolfe's investment philosophy is centered on backing companies that are building the future, often in areas previously considered science fiction. His portfolio spans a diverse range of sectors including artificial intelligence (AI), biotechnology, robotics, space exploration, synthetic biology, and advanced manufacturing. He seeks out founders who are not just innovating, but fundamentally reinventing industries with groundbreaking scientific and engineering breakthroughs. This focus on foundational technologies has allowed Lux Capital to invest in companies poised for significant long-term impact.

Wolfe's career background is deeply rooted in his passion for science and technology. Before co-founding Lux Capital, he cultivated a keen understanding of emerging technologies, which he has leveraged to build a firm known for its prescient investments. He is a prolific writer and speaker, frequently sharing his insights on the future of technology, the nature of innovation, and the venture capital ecosystem. His perspectives are often sought after by entrepreneurs, investors, and policymakers alike, reflecting his influence in shaping the discourse around technological progress.

Among Josh Wolfe's notable investments are companies that have achieved significant milestones and exits. These include Desktop Metal, a leader in additive manufacturing; Clarifai, an AI company focused on computer vision; Eikon Therapeutics, a drug discovery company; and Recursion Pharmaceuticals, which leverages AI for drug development. He also backed Auris Health, a robotic surgical platform acquired by Johnson & Johnson, demonstrating his ability to spot transformative technologies early. Other significant investments include Kallyope and numerous other ventures pushing the frontiers of science and engineering. Through these investments, Josh Wolfe continues to champion the development of technologies that promise to redefine human capabilities and solve some of the world's most complex challenges. His strategic vision and commitment to deep tech make him a pivotal force in the venture capital world.